Spyre Therapeutics, Inc. SYRE Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $97.19M+100% | $85.72M-4.1% | $64.9M-9.3% | $81.66M+79.6% | $48.49M-78.7% | ||
| $644.28M+24.8% | $670.81M+30.6% | $421.3M+23.0% | $444.92M+16.8% | $516.33M+101% | ||
| $22.49M+354% | $21.25M+295% | $18.41M+169% | $12.25M+25.8% | $4.95M+88.0% | ||
| $419.2M+14.2% | $440.9M+30.3% | $276.69M+9.1% | $327.76M+21.0% | $367.11M+92.1% | ||
| $56.95M— | $26.68M— | —— | —— | —— | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.7% | $569.77M+16.9% | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.6% | $569.78M+16.9% | ||
| $29.16M+34.8% | $26.95M-2.8% | $23.83M+81.2% | $19.42M+242% | $21.63M+0.2% | ||
| $5.07M+225% | $7.94M+39.6% | $5.13M+29.4% | $3.29M+23.5% | $1.56M-37.7% | ||
| $85.16M+20.5% | $58.69M+8.6% | $46.27M-19.6% | $83.06M+275% | $70.68M+65.1% | ||
| $1.29M— | $0— | —— | —— | —— | ||
| $56.95M-34.7% | $26.68M-70.6% | $49.5M-47.2% | $83.06M+34.7% | $87.17M+6.4% | ||
| 400M0.0% | 400M+3,076,823% | 400M0.0% | 400M0.0% | 400M0.0% | ||
| $1.71B+27.5% | $1.69B+26.4% | $1.36B+25.5% | $1.35B+26.9% | $1.34B+73.1% | ||
| -$1.2B-17.6% | -$1.13B-16.0% | -$1.07B-16.3% | -$1.05B-24.4% | -$1.02B-25.8% | ||
| -$767K-212% | $869K+383% | $791K-45.7% | $454K+182% | $682K+288% | ||
| $670.81M+39.0% | $715.24M+38.1% | $455.1M+39.0% | $455.77M+21.7% | $482.61M+217% | ||
| $763.95M+34.1% | $777.78M+27.8% | $504.6M+19.8% | $538.83M+23.6% | $569.78M+16.9% | ||
| $645.05M+25.1% | $669.94M+30.5% | $420.51M+23.2% | $444.47M+16.5% | $515.68M+100% | ||
| $0— | $0— | $8M— | $0— | $0— | ||
| $0— | $0— | $8M— | $0— | $0— | ||
| $432M+311% | $180.96M-27.4% | $39.47M+5.1% | $170.61M-44.8% | $105.15M-42.6% | ||
| $432M+311% | $180.96M-27.4% | $39.47M+5.1% | $170.61M-44.8% | $105.15M-42.6% | ||
| $1.06M+557% | $116K-76.5% | $38K+90.0% | $153K-77.3% | $161K-64.3% | ||
| $0— | $0— | $8M— | $0— | $0— | ||
| $432M+311% | $180.96M-27.4% | $47.47M+26.4% | $170.61M-44.8% | $105.15M-42.6% | ||
| $432M+311% | $180.96M-27.4% | $39.47M+5.1% | $170.61M-44.8% | $105.15M-42.6% | ||
| $432M+311% | $180.96M-27.4% | $47.47M+26.4% | $170.61M-44.8% | $105.15M-42.6% | ||
| $644.28M+24.8% | $670.81M+30.6% | $421.3M+23.0% | $444.92M+16.8% | $516.33M+101% | ||
| $741.5M— | —— | —— | —— | —— | ||
| $645.05M+25.1% | $669.94M+30.5% | $420.51M+23.2% | $444.47M+16.5% | $515.68M+100% | ||
| $50.26M+17.4% | $22.82M-9.0% | $11.02M-55.5% | $59.9M+2,169% | $42.81M+1,553% | ||
| $50.26M+17.4% | $22.82M-9.0% | $11.02M-55.5% | $59.9M+2,169% | $42.81M+1,553% | ||
| $1.42M+129% | $1.4M+112% | $1.12M-0.9% | $867K+68.3% | $621K-13.8% | ||
| $6.69M-59.4% | $3.86M-89.5% | $3.23M-91.1% | $0-100% | $16.49M-57.8% | ||
| $29.16M+34.8% | $26.95M-2.8% | $23.83M+81.2% | $19.42M+242% | $21.63M+0.2% | ||
| $0— | $0— | $8K— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 78.8M+30.8% | 78.2M+29.8% | 60.5M+17.7% | 60.4M+18.9% | 60.3M+64.6% | ||
| $1.71B+27.5% | $1.69B+26.4% | $1.36B+25.5% | $1.35B+26.9% | $1.34B+73.1% | ||
| $15K+15.4% | $15K+15.4% | $13K+8.3% | $13K+8.3% | $13K+30.0% | ||
| $432M+311% | $180.96M-27.4% | $47.47M+26.4% | $170.61M-44.8% | $105.15M-42.6% | ||
| $290K-64.1% | $986K+51.5% | $829K-41.7% | $607K+649% | $807K+1,423% | ||
| $1.06M+557% | $116K-76.5% | $38K+90.0% | $153K-77.3% | $161K-64.3% | ||
| $645.05M+25.1% | $669.94M+30.5% | $420.51M+23.2% | $444.47M+16.5% | $515.68M+100% | ||
| $56.95M— | $26.68M— | —— | —— | —— | ||
| $22.5M+18.0% | $17.42M-16.5% | $17.4M+131% | $15.02M+562% | $19.08M+5.1% | ||
| $1.42M+129% | $1.4M+112% | $1.12M-0.9% | $867K+68.3% | $621K-13.8% | ||
| $1.06M+557% | $116K-76.5% | $38K+90.0% | $153K-77.3% | $161K-64.3% | ||
| $290K-64.1% | $986K+51.5% | $829K-41.7% | $607K+649% | $807K+1,423% | ||
| $645.05M+25.1% | $669.94M+30.5% | $420.51M+23.2% | $444.47M+16.5% | $515.68M+100% | ||
| $419.2M+14.2% | $440.9M+30.3% | $276.69M+9.1% | $327.76M+21.0% | $367.11M+92.1% | ||
| $0— | $0-100% | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | $400M0.0% | ||
| $78.84M+30.8% | $78.19M+29.8% | $60.47M+17.7% | $60.37M+18.9% | $60.28M+64.6% | ||
| $78.84M+30.8% | $78.19M+29.8% | $60.47M+17.7% | $60.37M+18.9% | $60.28M+64.6% | ||
| $0— | $0— | $8K— | $0— | $0— | ||
| $432M+311% | $180.96M-27.4% | $39.47M+5.1% | $170.61M-44.8% | $105.15M-42.6% | ||
| $0— | $0— | $8M— | $0— | $0— | ||
| $1.06M+557% | $116K-76.5% | $30K+50.0% | $153K-77.3% | $161K-64.3% | ||
| $225.08M+50.8% | $229.92M+31.2% | $144.61M+62.4% | $117.16M+6.5% | $149.22M+126% | ||
| $1.06M+557% | $116K-76.5% | $38K+90.0% | $153K-77.3% | $161K-64.3% | ||
| $432M+311% | $180.96M-27.4% | $47.47M+26.4% | $170.61M-44.8% | $105.15M-42.6% | ||
| $56.95M— | $26.68M— | —— | —— | —— | ||
| $6.69M-59.4% | $3.86M-89.5% | $3.23M-91.1% | $0-100% | $16.49M-57.8% | ||
| 20.0% | —— | 20.0% | 20.0% | 20.0% | ||
| $165K-55.5% | $179K-64.3% | $170K-67.7% | $242K+3.0% | $371K+69.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Spyre Therapeutics, Inc.'s total assets?
- Spyre Therapeutics, Inc. (SYRE) holds $764.0M in total assets, up 34.1% year over year.
- How much cash does Spyre Therapeutics, Inc. have?
- Spyre Therapeutics, Inc. holds $97.2M in cash and equivalents.
- Can Spyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.97 — current assets exceed current liabilities.
- Where does Spyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.